Search Results

FDA warns about several Genzyme-manufactured products

Source: Reactions, Volume 1, Number 1279, 2009-11-21 , pp. 4-4(1)

Publisher: Adis International

Sibutramine under FDA review for cardiovascular risk

Source: Reactions, Volume 1, Number 1280, 2009-11-28 , pp. 2-2(1)

Publisher: Adis International

US FDA announces launch of Safe Use Initiative

Source: Reactions, Volume 1, Number 1278, 2009-11-14 , pp. 1-1(1)

Publisher: Adis International

A `dietary supplement' marketed for sexual enhancement has been found to illegally contain an undeclared pharmaceutical agent

Source: Reactions, Volume 1, Number 1278, 2009-11-14 , pp. 4-4(1)

Publisher: Adis International

FDA targets misconduct in new product development

Source: Reactions, Volume 1, Number 1265, 2009-08-15 , pp. 2-2(1)

Publisher: Adis International

The US FDA has issued guidance on preventing melamine contamination during drug manufacturing or drug compounding.

Source: Reactions, Volume 1, Number 1265, 2009-08-15 , pp. 3-3(1)

Publisher: Adis International

US FDA pushes for mandatory electronic AE reporting

Source: Reactions, Volume 1, Number 1267, 2009-08-29 , pp. 2-2(1)

Publisher: Adis International

Sabril [vigabatrin] has been approved by the US FDA, with a boxed warning with regard to vision damage.

Source: Reactions, Volume 1, Number 1267, 2009-08-29 , pp. 3-3(1)

Publisher: Adis International

New FDA recommendations for lenalidomide and skin reactions

Source: Reactions, Volume 1, Number 1259, 2009-07-04 , pp. 3-3(1)

Publisher: Adis International

FDA takes actions to reduce risk of dextropropoxyphene OD

Source: Reactions, Volume 1, Number 1260, 2009-07-11 , pp. 2-2(1)

Publisher: Adis International

The US FDA has approved dronedarone [Multaq] tablets for heart rhythm disorders with a boxed warning that it should not be used in

Source: Reactions, Volume 1, Number 1260, 2009-07-11 , pp. 3-3(1)

Publisher: Adis International

The US FDA has approved the blood-thinning drug prasugrel [Effient] with a boxed warning that it can sometimes cause serious haemorrhage.

Source: Reactions, Volume 1, Number 1261, 2009-07-18 , pp. 3-3(1)

Publisher: Adis International

FDA is reviewing safety of omalizumab

Source: Reactions, Volume 1, Number 1262, 2009-07-25 , pp. 2-2(1)

Publisher: Adis International

Teva Pharmaceuticals, US, has voluntarily recalled certain lot numbers of propofol injectable emulsion

Source: Reactions, Volume 1, Number 1262, 2009-07-25 , pp. 2-2(1)

Publisher: Adis International

The US FDA has approved Onsolis [fentanyl] for breakthrough pain in cancer patients aged ≥ 18 years who already use opioids around the clock

Source: Reactions, Volume 1, Number 1262, 2009-07-25 , pp. 2-2(1)

Publisher: Adis International

Propylthiouracil may cause serious liver injury, warns FDA

Source: Reactions, Volume 1, Number 1256, 2009-06-13 , pp. 2-2(1)

Publisher: Adis International

The US FDA and the International Serious Adverse Event Consortium (SAEC) has identified a genetic link associated with liver injury in some patients who receive flucloxacillin.

Source: Reactions, Volume 1, Number 1256, 2009-06-13 , pp. 3-3(1)

Publisher: Adis International

The US FDA warns against using Clarcon skin products after high levels of disease-causing bacteria were detected

Source: Reactions, Volume 1, Number 1256, 2009-06-13 , pp. 4-4(1)

Publisher: Adis International

FDA orders revised labelling for OTC analgesics, antipyretics

Source: Reactions, Volume 1, Number 1250, 2009-05-02 , pp. 3-3(1)

Publisher: Adis International

Stronger warnings for botulinum toxin products

Source: Reactions, Volume 1, Number 1251, 2009-05-09 , pp. 2-2(1)

Publisher: Adis International